AbbVie Inc. $ABBV Shares Sold by PKO Investment Management Joint Stock Co

Key Points

• PKO Investment Management reduced its stake in AbbVie by 35.4% in Q4, selling 12,584 shares and leaving 23,000 shares valued at about $5.26 million.
• AbbVie beat Q1 earnings and raised its 2026 outlook, with immunology drugs Skyrizi and Rinvoq helping offset Humira declines and prompting multiple analyst upgrades and higher price targets.
• There was notable insider selling (SVP David Purdue sold 5,230 shares; EVP Perry Siatis sold 22,381 shares), the company declared a $1.73 quarterly dividend (3.3% yield), and the stock was down roughly 2.2%.

PKO Investment Management Joint Stock Co lessened its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 35.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 23,000 shares of the company's stock after selling 12,584 shares during the quarter. PKO Investment Management Joint Stock Co's holdings in AbbVie were worth $5,255,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Chelsea Counsel Co. purchased a new position in AbbVie in the third quarter worth approximately $26,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie in the 4th quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the 3rd quarter valued at approximately $31,000. WestEnd Advisors LLC raised its holdings in shares of AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock valued at $32,000 after purchasing an additional 85 shares in the last quarter. Finally, Caitlin John LLC purchased a new stake in shares of AbbVie during the 3rd quarter worth $33,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

AbbVie Stock Down 2.2%

NYSE:ABBV opened at $206.63 on Friday. The company has a market capitalization of $365.36 billion, a PE ratio of 101.79, a P/E/G ratio of 0.74 and a beta of 0.32. AbbVie Inc. has a 52-week low of $176.57 and a 52-week high of $244.81. The stock's 50 day moving average price is $214.55 and its 200 day moving average price is $221.54.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analysts' expectations of $14.72 billion. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The firm's revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.46 earnings per share. As a group, sell-side analysts anticipate that AbbVie Inc. will post 14.29 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie's dividend payout ratio is currently 340.89%.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Guggenheim reaffirmed a "buy" rating and set a $249.00 price target on shares of AbbVie in a report on Friday. Bank of America raised AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 target price on the stock in a research report on Thursday. Cantor Fitzgerald restated an "overweight" rating and set a $240.00 target price on shares of AbbVie in a research note on Thursday. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a report on Thursday, February 5th. Finally, Berenberg Bank set a $275.00 price target on shares of AbbVie in a research note on Tuesday, January 20th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the company's stock. According to data from MarketBeat, AbbVie presently has an average rating of "Moderate Buy" and an average target price of $252.90.

Insiders Place Their Bets

In other news, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company's stock, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is owned by corporate insiders.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.